ENXTBR:ARGXBiotechs
Assessing Argenx (ENXTBR:ARGX) Valuation After Broad FDA Label Expansion For VYVGART
argenx (ENXTBR:ARGX) is back in focus after the U.S. Food and Drug Administration approved a label expansion for VYVGART and VYVGART Hytrulo, covering all adult generalized myasthenia gravis serotypes.
See our latest analysis for argenx.
Despite the strong news flow around VYVGART and a recent earnings update, argenx’s share price return has been slightly weaker in the short term, with the stock down 3.43% over 30 days and 4.23% year to date. Longer term total shareholder returns of 36.73%...